The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood

Cancer Research

Volumn 57, Issue 2, 1997, Pages 304-309

  Pollack, Ian F ^a,c,d   Hamilton, Ronald L ^a,c,d   Finkelstein, Sydney D ^a   Campbell, Jeffrey W ^a   Martinez, A Julio ^a,c   Sherwin, Richard N ^e   Bozik, Michael E ^a,c   Gollin, Susanne M ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e EMORY AND HENRY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; LOMUSTINE; MESNA; PREDNISONE; PROTEIN P53; VINCRISTINE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; GLIOBLASTOMA; HUMANS; INFANT; MALE; POINT MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031032368     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Pollack, I. F. Current concepts: brain tumors in children. N. Engl. J. Med., 331: 1500-1507, 1994.
2. Young, J. L., and Miller, R. W. Incidence of malignant tumors in U. S. children. J. Pediatr., 86: 254-258, 1975.
3. Finlay, J. L. Chemotherapeutic strategies for high-grade astrocytomas of childhood, In: R. J. Packer, W. A. Bleyer, and C. Pochedly (eds.), Pediatric Neuro-oncology, Vol. 3, pp. 176-206. Chur, Switzerland: Harwood Academic Publishers, 1992.
4. Devaux, B. C., O'Fallon, J. R., and Kelly, P. J. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J. Neurosurg., 78: 767-775, 1993.
5. Nazzaro, J. M., and Neuwelt, E. A. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J. Neurosurg., 73: 331-344, 1990.
6. Chandler, K. L., Prados, M. D., Malec, M., and Wilson, C. B. Long-term survival in patients with glioblastoma multiforme. Neurosurgery (Baltimore), 32: 716-720, 1993.
7. Salcman, M., Scholtz, H., Kaplan, R. S., and Kulik, S. Long-term survival in patients with malignant astrocytoma. Neurosurgery (Baltimore), 34: 213-220, 1994.
8. Salford, L. G., Brun, A., and Nirfalk, S. Ten-year survival among patients with supratentorial astrocytoma grade III and IV. J. Neurosurg, 69: 506-509, 1988.
9. Campbell, J., Pollack, I. F., Shultz, B. L., and Martinez, A. J. Prognostic factors in the management of pediatric malignant gliomas. Neurosurgery (Baltimore), 38: 258-264, 1996.
10. Litofsky, N. S., Hinton, D., and Raffel, C. The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery (Baltimore). 34: 967-973, 1994.
11. Rasheed, B. K. A., McLendon, R. E., Herndon, R. E., Friedman, H. S., Friedman, A. H., Bigner, D. D., and Bigner, S. H. Alterations of the TP53 gene in human gliomas. Cancer Res., 54: 1324-1330, 1994.
12. Lang, F. F., Miller, C. C., Pisharody, S., Koslow, M., and Newcomb, E. W. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene, 9: 949-954, 1994.
13. Fults, D., Brockmeyer, D., Tullous, M. W., Pedone, C. A., and Cawthond R. M. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during astrocytoma progression. Cancer Res., 50: 674-679, 1992.
14. von Deimling, A., Eibl, R. H., Ohgaki, H., Louis, D. N., von Ammon, K., Petersen, I., Kleihues, P., Chung, R. Y., Wiestler, O. D., and Seizinger, B. R. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res., 52: 2987-2990, 1992.
15. Sidransky, D., Mikkelsen, T., Schechheimer, K., Rosenblum, M. L., Cavenee, W., and Vogelstein, B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature (Lond.), 355: 846-847, 1992.
16. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis: its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
17. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
18. Kinzler, K. W., and Vogelstein, B. Cancer therapy meets p53. N. Engl. J. Med., 331: 49-50, 1994.
19. Lowe, S., Bodis, S., McClatchy, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
20. Rusch, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., Kris, M., and Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res., 55: 5038-5042, 1995.
21. Esrig, D., Elmajian, D., Groshen, S., Freeman, F. A., Stein, J. P., Chen, S-C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
22. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993.
23. Goh, H-S., Yao, J., and Smith, D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res., 55: 5217-5221, 1995.
24. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
25. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W-W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
26. Sposto, R., Ertel, I. J., Jenkin, R. D. T., Boesel, C. P., Venes, J. L., Ortega, J. A., Evans, A. E., Wara, W., and Hammond, D. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. J. Neuro-oncol., 7: 165-177, 1989.
27. Pendergrass, T. W., Milstein, J. M., Geyer, J. R., Mulne, A. F., Kosnik, E. J., Morris, J. D., Heideman, R. L., Ruymann, F. B., Stuntz, J. T., and Bleyer, W. A. Eight drugs in one-day chemotherapy for brain tumors: experience with 107 children and rationale for preradiation chemotherapy. J. Clin. Oncol., 5: 1221-1231, 1987.
28. Kleihues, P., Burger, P. C., and Scheithauer, B. W. Histological typing of tumours of the central nervous system. In: L. H. Sobin (ed.), International Histological Classification of Tumours. Vol. 21. Ed. 2, pp. 11-16. Geneva: Springer-Verlag, 1993.
29. Shi, S. R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39: 741-748, 1991.
30. Lane, D. P., and Benchimol, S. p53: oncogene or anti-oncogene. Genes Dev., 4: 1-8, 1990.
31. Hsu, S., Raine, L., Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J. Histochem. Cytochem., 29: 577-580, 1981.
32. Hollstein, M., Sidransky, D., Vogelstetn, B., and Harris, C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
33. Finkelstein, S. D., Sayegh, R., Christensen, S., and Swalsky, P. A. Genotypic classification of colorectal adenocarcinoma, Cancer (Phila.), 71: 3827-3838, 1993.
34. Kim, B., Finn, L., Martinez, A. J., Campbell, J., Pollack, I., Bakker, A., Swalsky, P. A., and Finkelstein, S. D. Role of p53 gene alterations in pediatric high grade gliomas. Proceedings of the 84th Annual Meeting of the United States and Canadian Academy of Pathology, Toronto, Ontario, Canada, 1995.
35. Kaplan, E. L., and Meier, P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
36. Mantel, N. W. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
37. Artico, M., Cervoni, L., Celli, P., Salvati, M., and Palma, L. Supratentorial glioblastoma in children: a series of 27 surgically treated cases. Child's Nerv. Syst., 9: 7-9, 1993.
38. Dohrman, G. J., Farwell, J. R., and Flannery, J. T. Glioblastoma multiforme in children. J. Neurosurg., 44: 442-448, 1976.
39. Dropcho, E., Wisoff, J., Walker, R., and Allen, J. C. Supratentorial malignant gliomas in childhood: a review of fifty cases. Ann. Neurol., 22: 355-364, 1978.
40. Phuphanich, S., Edwards, M. S. B., Levin, V. A., Vestnys, P. S., Wara, W. M., Davis, R. L., and Wilson, C. B. Supratentorial malignant gliomas of childhood: results of treatment with radiation therapy and chemotherapy. J. Neurosurg., 60: 495-499, 1984.
41. Seaward, S., Goldwein, J., Needle, M., Sutton, L. N., Phillips, P., Rorke, L., and D'Angio, G. Malignant gliomas in children: patterns of presentation, treatment and prognostic factors. Pediatr. Neurosurg., 21: 156-157, 1994.
42. Wisoff, J. H., Boyett, J., Brandt, K., Finlay, J. L., and Berger, M. S. Neurosurgical management and influence of extent of resection on survival in pediatric high-grade astrocytomas: a report on CCG 945. J. Neurosurg., 78: 344A, 1993.
43. Finlay, J. L., Boyett, J. M., Yates, A. J., Wisoff, J. H., Milstein, J. M., Geyer, J. R., Bertolone, S. J., McGuire, P., Cherlow, J. M., Tefft, M., Turski, P. A., Wara, W. M., Edwards, M., Sutton, L. N., Berger, M. S., Epstein, F., Ayers, G., Allen, J. C., and Packer, R. J. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J. Clin. Oncol., 13: 112-123, 1995.
44. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
45. Louis, D. N., Rubio, M. P., Correa, K. M., Gusella, J. F., and von Deimling, A. Molecular genetic of pediatric brainstem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J. Neuropathol. Exp. Neurol., 52: 507-515, 1993.
46. Louis, D. N. The p53 gene and protein in human brain tumors. J. Neuropathol. Exp. Neurol., 53: 11-21, 1994.
47. Louis, D. N., von Deimling, A., Chung, R. Y., Rubio, M-P., Whaley, J. M., Eibl, R. H., Ohgaki, H., Wiestler, O., Thor, A. D., and Seizinger, B. R. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. Exp. Neurol., 52: 31-38, 1993.
48. Alderson, L. M., Castleberg, R. L., Harsh, G. R., IV. Louis, D. N., and Henson, J. W. Human gliomas with wild-type p53 express bcl-2. Cancer Res., 55: 999-1001, 1995.
49. Danks, R. A., Chopra, G., Gonzales, M. F., Orian, J. M., and Kaye, A. H. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma, Neurosurgery (Baltimore), 37: 246-254, 1995.
50. Jaros, E., Perry, R. H., Adam, L., Kelly, P. J., Crawford, P. J., Kalbag, R. M., Mendelow, A. D., Sengupta, R. P., and Pearson, A. D. J. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br. J. Cancer, 66: 373-385, 1992.
51. Soini, Y., Niemela, A., Kamel, D., Herva, R., Bloigu, R., Paakko, P., and Vahakangas, K. p53 immunohistochemical positivity as a prognostic marker in intracranial tumors. APMIS 102: 786-792, 1994.
52. Chozick, B. S., Pezzullo, J. C., Epstein, M. H., and Finch, P. W. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery (Baltimore), 35: 831-837, 1994.
53. Kyritsis, A. P., Bondy, M. L., Hess, K. R., Cunningham, J. E., Khu, D., Amos, C. J., Yung, W. K. A., Levin, V. A., and Bruner, J. M. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin. Cancer Res., 1: 1617-1622, 1995.
54. Montine, T. J., Bruner, J. M., Vandersteenhoven, J. J., Dodge, R. K., and Burger, P. C. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn. Molec. Pathol., 3: 240-245, 1994.
55. Al-Sarraj, S., and Bridges, L. R. p53 immunoreactivity in astrocytomas and its relationship to survival. Br, J. Neurosurg., 9: 143-149, 1995.
56. Duffner, P. K., Krischer, J. P., Burger, P. C., Cohen, M. E., Backstrom, J. W., Horowitz, M. E., Sanford, R. A., Friedman, H. S., and Kun, L. E. Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J. Neuro-oncol., 28: 245-256, 1996.